Navigation Links
Raptor Pharmaceuticals Corp. and TorreyPines Complete Merger
Date:9/30/2009

livery of new treatment options to patients by working to improve existing therapeutics through the application of highly specialized drug targeting platforms and formulation expertise. The Company focuses on underserved patient populations where it can have the greatest potential impact and currently has product candidates in clinical development designed to treat nephropathic cystinosis, non-alcoholic steatohepatitis ("NASH"), Huntington's Disease ("HD"), aldehyde dehydrogenase ("ALDH2") deficiency and a non-opioid solution designed for chronic pain.

The Company's preclinical programs are based upon bioengineered novel drug candidates and drug-targeting platforms derived from the human receptor-associated protein ("RAP") and related proteins that are designed to target cancer, neurodegenerative disorders and infectious diseases.

For additional information, please visit www.raptorpharma.com.

FORWARD LOOKING STATEMENTS

This document contains forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements relate to future events or our future results of operation or future financial performance, including, but not limited to the following statement: that a NASDAQ listing will create liquidity for the combined company's common stock or better access to capital markets for the combined company; that the combined company will announce clinical or strategic milestones as anticipated; and that any of the Company's drug product programs will be successful
'/>"/>

SOURCE Raptor Pharmaceuticals Corp.; TorreyPines Therapeutics
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Raptor Pharmaceuticals Receives Notices of Allowance for Two NeuroTrans(TM) Patent Applications
2. Raptor Pharmaceuticals Appoints Dr. Patrice P. Rioux as Chief Medical Officer
3. Raptor Pharmaceuticals Announces Completion of Patient Enrollment in Phase 2a Clinical Trial in Non-Alcoholic Steatohepatitis (NASH)
4. Raptor Pharmaceuticals Corp. Announces Positive Phase IIa Clinical Study Results for Convivia(TM) Program
5. Raptor Pharmaceuticals to Collaborate with Centre Hospitalier Universitaire dAngers for Phase II Clinical Trial in Huntingtons Disease
6. Raptor Pharmaceuticals Provides Update on Targeting Platforms
7. Raptor Pharmaceuticals Announces Phase 2a Clinical Trial Initiation in Non-Alcoholic Steatohepatitis (NASH)
8. Raptor Pharmaceuticals Enters Collaboration Agreement with UC San Diego in Liver Disease
9. Raptor Pharmaceuticals Corp. Initiates Phase IIa Clinical Study for Convivia(TM)
10. Raptor Pharmaceuticals Provides Update of Product Programs
11. Arena Pharmaceuticals Reports Positive, Highly Significant BLOSSOM Trial Results for Weight Management; NDA Submission on Track for December
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2015)... 31, 2015  In today,s ever-changing marketplace, call centers ... mobile, increasingly connected, and increasingly impatient with slow service. ... interaction channels and tools is driving call centers to ... According to research by benchmarking firm, Best ... segment in a call center study realize the impact ...
(Date:7/31/2015)... 31, 2015 More than 1,500 substance abuse ... convene in Indianapolis Aug. 2-6 ... Mid-Year Training Institute . The week-long training, held at ... one of our nation,s biggest public health challenges – ... Institute is a one-of-a-kind intensive training opportunity, offering more ...
(Date:7/31/2015)... July 31, 2015 RnRMarketResearch.com ... market research report that provides an overview of ... data sourced from in-house databases, secondary and primary ... needles market products pipeline spread across 124 pages, ... 73 tables and 5 figures is now available ...
Breaking Medicine Technology:Best Practices in Building World-Class Consumer & Over-the-Counter Call Centers 2Community Leaders From Across The Country Head To Indianapolis For CADCA 2015 Mid-Year Training Institute Aug. 2-6 2Syringes and Needles Market Products Pipeline Review 2015 Report 2Syringes and Needles Market Products Pipeline Review 2015 Report 3Syringes and Needles Market Products Pipeline Review 2015 Report 4Syringes and Needles Market Products Pipeline Review 2015 Report 5
... DUBLIN, Feb. 15, 2011 Warner Chilcott plc (Nasdaq: ... and full year 2010 financial results prior to the market opening ... issuing a press release, the Company will host a conference call ... AM (Eastern Time) to review the results. To participate in the ...
... Boston Scientific Corporation (NYSE: BSX ) ... treat peripheral chronic total occlusions (CTOs).  These acquisitions add ... devices for lower extremity peripheral artery disease.   ... 2010 from S.I. Therapies, Ltd., based in Israel.  The ...
Cached Medicine Technology:Boston Scientific Acquires Two Novel Technologies to Treat Peripheral Chronic Total Occlusions 2Boston Scientific Acquires Two Novel Technologies to Treat Peripheral Chronic Total Occlusions 3Boston Scientific Acquires Two Novel Technologies to Treat Peripheral Chronic Total Occlusions 4
(Date:8/3/2015)... ... August 03, 2015 , ... Pitt Researchers ... the University of Pittsburgh School of Medicine are leading a five-year, $5 million ... sub-Saharan Africa. , A cooperative agreement awarded by the U.S. Agency for ...
(Date:8/3/2015)... Irving, Texas (PRWEB) , ... August 03, 2015 ... ... awarded an agreement to Seattle-based Genelex to offer pharmacogenetic lab testing and ... care and reduce health care costs. , Annually, more than 8.6 million ...
(Date:8/3/2015)... ... 2015 , ... Catalent Pharma Solutions, the leading global provider ... products, today welcomed the announcement by OPKO Health that the US Food and ... treatment for chronic kidney disease (CKD) and vitamin D insufficiency, which uses Catalent’s ...
(Date:8/3/2015)... Angeles, CA (PRWEB) , ... August 03, 2015 , ... ... dental services to help patients in need. Most people know that general health emergencies, ... emergency. Unfortunately, a fewer amount of people know where to turn to during a ...
(Date:8/3/2015)... , ... August 03, 2015 , ... ... of its industry-defining contract lifecycle management solution, as well as announced the date ... increase the speed and ease of contract management tasks as well as enhancements ...
Breaking Medicine News(10 mins):Health News:$5M Effort to Guide Use of HIV Prevention Meds in Africa 2Health News:$5M Effort to Guide Use of HIV Prevention Meds in Africa 3Health News:$5M Effort to Guide Use of HIV Prevention Meds in Africa 4Health News:Novation Awards Genelex First Group Purchasing Agreement for Pharmacogenetic Testing and Precision Medicine Software 2Health News:Novation Awards Genelex First Group Purchasing Agreement for Pharmacogenetic Testing and Precision Medicine Software 3Health News:Catalent’s OptiShell™ Technology is Delivery Platform for OPKO Health’s New Chronic Kidney Disease Treatment 2Health News:Catalent’s OptiShell™ Technology is Delivery Platform for OPKO Health’s New Chronic Kidney Disease Treatment 3Health News:Los Angeles Dental Practice, Sunset Plaza Dental, Now Offers Emergency Dental Services 2Health News:Los Angeles Dental Practice, Sunset Plaza Dental, Now Offers Emergency Dental Services 3Health News:Novatus Unveils Milestone Software Release 2
... With changes in the nation,s healthcare system looming and overall ... for debut at the Wynn Las Vegas this November has ... into alternative careers. The Medical Fusion conference ( ... that is tapping into the growing frustration of physicians practicing ...
... Patient-360(TM) tool optimizes impact of patient education programs. ... For marketers in the pharmaceutical industry, building relationships ... Data Development Worldwide,s Patient-360(TM) market research tool allows ... the patient pathway and then to prioritize and ...
... staph bacteria is being transmitted between animals and ... News) -- Transmission of methicillin-resistant staphylococcus aureus (MRSA) ... the most common being infections of the skin, ... a review of clinical evidence. , "Pet owners ...
... succeed where others have failed , MONDAY, June 22 (HealthDay ... in the United States could prove to be the toughest ... can reach that long-elusive goal, it would not only guarantee ... history, experts say. , "Assuming that President Obama ...
... with Patient and Chamber , , ANAHEIM, Calif., June ... in technology for hyperbaric healthcare, today announced the availability of ... verification of all NFPA (National Fire Protection Association) ... to be fully integrated into any hyperbaric chamber. The new ...
... Meeting -- , , News Facts , , ... new report, IDC Health Insights , an advisory services ... ranked Oracle as the number one vendor for enterprise life sciences software ... Software Top 10 identifies the 10 leading enterprise and specialty software vendors ...
Cached Medicine News:Health News:Physician Dissatisfaction Leads to New Medical Conference 2Health News:Physician Dissatisfaction Leads to New Medical Conference 3Health News:Data Development Worldwide Helps Pharmaceutical Marketers Optimize Relationship Marketing to Patients 2Health News:A Pet's Bite Can Pass on MRSA 2Health News:Health-Care Reform Could Be Obama's Toughest Challenge 2Health News:Health-Care Reform Could Be Obama's Toughest Challenge 3Health News:Health-Care Reform Could Be Obama's Toughest Challenge 4Health News:Sechrist Industries Introduces Ground-Check System to Verify NFPA Ground Requirements in Hyperbaric Chambers 2Health News:Market Research Firm Cites Oracle as Top Software Vendor for the Life Sciences Industry 2Health News:Market Research Firm Cites Oracle as Top Software Vendor for the Life Sciences Industry 3
Acuity Astigmatism: Letter Acuity, Astigmatic Clock, Number Acuity, and Tumbling E Tests....
... laboratory analysis that measures a substance produced by ... Annual PSA testing is a safe and effective ... as prostate cancer. One BIOSAFE Collection Kit, ... BIOSAFE's CLIA Certified Laboratory, and review of results ...
Stereo Smile II also includes a blank card and tests,at 60, 120, 240 and 480 sec of arc., ,Smile Test II Includes:, 1 demonstration card, 1 pair pediatric 3-D viewers, 1 pair infant 3-D v...
... from 800 to 40 seconds ... as 2 years of age ... left to right., ,Randot Preschool ... #1: 200 & 100 sec ...
Medicine Products: